Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

NCT04210037 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

28

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Small Cell Lung Cancer

Interventions

DRUG: APG-1252
DRUG: Paclitaxel

Sponsor

Ascentage Pharma Group Inc.